Celyad Oncology S.A.
CYAD · NASDAQ
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1,128.6% | -75.9% | 31.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 98.3% | 35.7% | 56.9% | -902.3% |
| R&D Expenses | $2 | $2 | $3 | $2 |
| G&A Expenses | $1 | $2 | $2 | $4 |
| SG&A Expenses | $1 | $2 | $3 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$0 | $0 |
| Operating Expenses | $3 | $3 | $5 | $5 |
| Operating Income | -$3 | -$3 | -$5 | -$6 |
| % Margin | -1,613.4% | -22,021.4% | -8,124.1% | -13,236.4% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | $0 |
| Pre-Tax Income | -$3 | -$3 | -$5 | -$4 |
| Tax Expense | $0 | -$0 | -$0 | -$0 |
| Net Income | -$3 | -$3 | -$5 | -$4 |
| % Margin | -1,616.3% | -21,742.9% | -8,117.2% | -8,500% |
| EPS | -0.067 | -0.12 | -0.16 | -0.17 |
| % Growth | 44.1% | 25% | 5.9% | – |
| EPS Diluted | -0.067 | -0.12 | -0.16 | -0.17 |
| Weighted Avg Shares Out | 41 | 26 | 29 | 23 |
| Weighted Avg Shares Out Dil | 41 | 26 | 29 | 23 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$3 | -$4 | -$4 |
| % Margin | -1,646.5% | -19,921.4% | -7,703.4% | -10,040.9% |